XNAS · Healthcare · Biotechnology
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.86 | -0.83 | +3.49% | $60.1M | ✅ Beat | +2.23% | -1.08% | — |
| 2026-02-26 | Q4 2025 | -0.78 | -0.73 | +6.41% | $57.3M | ✅ Beat | +3.38% | -6.74% | -22.69% |
| 2025-11-04 |
| Q3 2025 |
| -0.72 |
| -0.82 |
| -13.89% |
| $51.3M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.67 | -0.75 | -11.94% | $48.5M | ❌ Miss | +0.50% | +8.91% | +18.06% |
| 2025-02-26 | Q4 2024 | -0.73 | -0.72 | +1.37% | $41.8M | ✅ Beat | -0.60% | -0.66% | +2.78% |
| 2024-11-05 | Q3 2024 | -0.80 | -0.73 | +8.75% | $33.3M | ✅ Beat | +11.38% | +13.88% | +2.79% |
| 2024-08-06 | Q2 2024 | -0.71 | -0.55 | +22.54% | $29.1M | ✅ Beat | -1.09% | +4.38% | +9.60% |
| 2024-05-07 | Q1 2024 | -2.16 | -2.35 | -8.80% | $26.0M | ❌ Miss | -1.09% | +2.62% | +0.84% |
Showing last 8 quarters.